Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HNF4A | P41235 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 8/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12501673 | 1.00 | HNF4A (0.37) | HNF4ACYP1A2TYRMEN1LMNA | |
| SCHEMBL22289856 | 0.84 | TYR (0.37) | CYP1A2TYRLMNAESR1ESR2 | |
| SCHEMBL32677689 | 0.84 | MEN1 (0.36) | HNF4ACYP1A2MEN1LMNAPOLB | |
| SCHEMBL29602086 | 0.80 | PDE2A (0.34) | KMT2AESR1ESR2PDE2A | |
| SCHEMBL9938343 | 0.80 | PLAU (0.36) | MEN1KMT2AALOX15CYP3A4HIF1A | |
| SCHEMBL15903816 | 0.80 | MEN1 (0.32) | CYP1A2TYRMEN1LMNAPOLB | |
| SCHEMBL670032 | 0.78 | HNF4A (0.35) | HNF4ACYP1A2TYRMEN1LMNA | |
| SCHEMBL12475251 | 0.77 | HPRT1 (0.52) | CYP1A2MEN1LMNAKMT2ACYP3A4 | |
| SCHEMBL30446008 | 0.77 | HPRT1 (0.52) | CYP1A2MEN1LMNAKMT2ACYP3A4 | |
| SCHEMBL159626 | 0.77 | HPRT1 (0.52) | CYP1A2MEN1LMNAKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261393-A1 | SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE | HDT BIO CORP. | 2024-08-08 | — | — | US | claimed |
| EP-4405372-A1 | SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE | HDT Bio Corp. (US) | 2024-07-31 | — | — | EP | claimed |
| WO-2023048759-A1 | SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE | HDT BIO CORP. (US) | 2023-03-30 | — | — | WO | claimed |
| EP-3229809-A1 | COMPOUNDS AND METHODS INVOLVING STEROLS | Warsaw Orthopedic, Inc. (US) | 2017-10-18 | — | — | EP | claimed |
| WO-2016094421-A1 | COMPOUNDS AND METHODS INVOLVING STEROLS | WARSAW ORTHOPEDIC, INC. (US) | 2016-06-16 | — | — | WO | claimed |
| WO-2026102175-A1 | NMDA RECEPTOR-MODULATORY COMPOUNDS AND METHODS OF USE THEREOF | Sage Therapeutics, LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4713445-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | Versiti Blood Research Institute Foundation, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260041754-A1 | NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY | HDT BIO CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250228930-A1 | SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE | HDT BIO CORP. | 2025-07-17 | — | — | US | disclosed |
| US-12350329-B2 | RNA vaccines against infectious diseases | HDT BIO CORP. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250152736-A1 | IMMUNE SYSTEM MODULATORS AND USES THEREOF | HDT BIO CORP. | 2025-05-15 | — | — | US | disclosed |
| US-12257299-B2 | SARS-CoV-2 RNA vaccine compositions and methods of use | HDT BIO CORP. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2017136549-A1 | COMPOUNDS FOR TREATING EYE DISORDERS OR DISEASES | YOUHEALTH BIOTECH, LIMITED (KY) | 2017-08-10 | — | — | WO | disclosed |
| WO-2016094421-A1 | COMPOUNDS AND METHODS INVOLVING STEROLS | WARSAW ORTHOPEDIC, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2015184668-A1 | ERGOSTEROL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 正源堂（天津滨海新区）生物科技有限公司 | 2015-12-10 | — | — | WO | disclosed |
| WO-2014132213-A1 | COMPOUNDS, PROCESSES FOR EXTRACTING THEM FROM KELP, COMPOSITIONS CONTAINING SAID COMPOUNDS AND USE OF SAID COMPOSITIONS | LAMICARE HEALTH LTD (GB) | 2014-09-04 | — | — | WO | disclosed |
| EP-2651916-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-2019620-A2 | IMPLANTABLE VOLTAIC CELL | Epps, Spencer J.G. (US) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007130694-A2 | IMPLANTABLE VOLTAIC CELL | EPPS SPENCER J G (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041754-A1 | NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY | ITGAL, ITGA2B, ITGA2 | HNF4A 1940/4885CYP1A2 3698/4885TYR 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.